<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960763</url>
  </required_header>
  <id_info>
    <org_study_id>TRD-1511-33321</org_study_id>
    <secondary_id>201609085</secondary_id>
    <secondary_id>R01MH114966-01</secondary_id>
    <nct_id>NCT02960763</nct_id>
  </id_info>
  <brief_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to assess which antidepressants work the best in older&#xD;
      adults who have treatment-resistant depression (TRD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Older adult participants with treatment-resistant depression will be randomly assigned to a&#xD;
      Step 1 medication strategy.&#xD;
&#xD;
        -  Adding aripiprazole to current antidepressant medication&#xD;
&#xD;
        -  Adding bupropion to current antidepressant medication&#xD;
&#xD;
        -  Replacing current antidepressant medication with bupropion&#xD;
&#xD;
      If depression is not relieved at the end of 10 weeks, or if participants do not qualify for&#xD;
      Step 1, participants will be randomly assigned to a Step 2 medication strategy:&#xD;
&#xD;
        -  Adding lithium to current antidepressant medication&#xD;
&#xD;
        -  Replacing current antidepressant medication with nortriptyline&#xD;
&#xD;
      All medication strategies will be offered in collaboration with participants' own physicians&#xD;
      with the the research team providing support and guidance.&#xD;
&#xD;
      After treatment in Step 1 and/or Step 2, participants will enter the Continuation Phase to&#xD;
      assess long term follow-up outcomes for 12 months.&#xD;
&#xD;
      Participants in this clinical trial will also be asked to participate in an additional study&#xD;
      to gather imaging and biomarker data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychological Well-Being</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Measured by NIH Toolbox Surveys: Positive Affect and General Life Satisfaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission from Depression</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Remission defined as Montgomery Asberg Depression Rating Scale score â‰¤10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Through study completion (20 weeks, 1 year and 10 weeks, or 1 year and 20 weeks)</time_frame>
    <description>Life threatening illness, hospitalization, or need of medical care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fall-related Injuries</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Injuries or impairment resulting from falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in executive function</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by composite variable of selected tasks from the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Delis-Kaplan Executive Function System (D-KEFS), and NIH Toolbox-Cognition battery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in episodic memory</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by composite variable of selected tasks from the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Delis-Kaplan Executive Function System (D-KEFS), and NIH Toolbox-Cognition battery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in executive-control and cortico-limbic circuitry</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma biomarkers</measure>
    <time_frame>Baseline, 6 months, 24 months</time_frame>
    <description>Measured by customized multiplex protein array platform from the Senescence Associated Secretory Protein (SASP) index, and markers of bone turnover, with DXA correlation of bone density.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Treatment-Refractory Depression</condition>
  <condition>Late Life Depression</condition>
  <condition>Geriatric Depression</condition>
  <arm_group>
    <arm_group_label>Aripiprazole Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Aripiprazole Augmentation</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Bupropion Augmentation</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to bupropion</intervention_name>
    <description>Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Switch to Bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.</description>
    <arm_group_label>Lithium Augmentation</arm_group_label>
    <other_name>Lithium carbonate</other_name>
    <other_name>Eskalith</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to nortriptyline</intervention_name>
    <description>Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml</description>
    <arm_group_label>Switch to Nortriptyline</arm_group_label>
    <other_name>Pamelor,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 60 and older&#xD;
&#xD;
          -  Current Major Depressive Disorder (MDD)&#xD;
&#xD;
          -  Failure to respond adequately to two or more antidepressant treatment trials of&#xD;
             recommended dose and length&#xD;
&#xD;
          -  Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective&#xD;
             disorder, schizophreniform disorder, delusional disorder, or current psychotic&#xD;
             symptoms&#xD;
&#xD;
          -  High risk for suicide and unable to be managed safely in the clinical trial&#xD;
&#xD;
          -  Contraindication to proposed study medications, as determined by study physician&#xD;
             including history of intolerance or non-response to proposed medications.&#xD;
&#xD;
          -  Non-correctable, clinically significant sensory impairment interfering with&#xD;
             participation&#xD;
&#xD;
          -  Unstable medical illness, including delirium, uncontrolled diabetes mellitus,&#xD;
             hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that&#xD;
             are not under medical management.&#xD;
&#xD;
          -  Moderate to severe substance or alcohol use disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lenard, MSW</last_name>
    <phone>314-747-5706</phone>
    <email>lenarde@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Schweiger, CCRC</last_name>
    <phone>314-362-3153</phone>
    <email>schweigj@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Late-Life Mood, Stress, and Wellness Research Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashlyn Applegate</last_name>
      <phone>310-206-5240</phone>
      <email>aapplegate@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raquel Hernandez Sotomayor</last_name>
      <phone>(310) 267-5264</phone>
      <email>RHernandezSotomayor@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Helen Lavretsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Healthy Mind Lab</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lenard, BA</last_name>
      <phone>314-747-5706</phone>
      <email>lenarde@psychiatry.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Schweiger, BA</last_name>
      <phone>314-362-3153</phone>
      <email>schweigj@psychiatry.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Lenze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Adult and Late Life Depression Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Montes Garcia</last_name>
      <phone>646-774-8648</phone>
      <email>carolina.montes@nyspi.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Brown, PhD</last_name>
      <phone>(646) 774-8666</phone>
      <email>pb2410@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Roose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J-1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athina Perivolaris, RN, MN</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32897</phone_ext>
      <email>athina.perivolaris@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Shima Ovaysikia, MA</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32589</phone_ext>
      <email>Shima.Ovaysikia@camh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Benoit Mulsant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aristotle Voineskos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Eric Lenze</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Comparative Effectiveness Research</keyword>
  <keyword>Pragmatic Clinical Trials</keyword>
  <keyword>Patient-Centered Outcomes Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A cleaned, complete, and de-identified copy of the final data set including administrative and technical metadata records will be made available through a Washington University in St. Louis (WUSTL) secure repository and registered at clinicaltrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

